Board of Directors approved the 2021 consolidated financial report
· Issued by Lumosa Therapeutics Co Ltd
Close
Today's Information
Provided by: LUMOSA THERAPEUTICS CO., LTD.
SEQ_NO
4
Date of announcement
2022/03/04
Time of announcement
16:30:43
Subject
LUMOSA Board of Directors approved the 2021
consolidated financial report
Date of events
2022/03/04
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/03/04
2.Date of the audit committee approved:2022/03/04
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2021/01/01~2021/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):17,362
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):9,889
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):(430,278)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):95,946
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):95,946
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):95,946
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):0.64
11.Total assets end of the period (thousand NTD):2,348,695
12.Total liabilities end of the period
(thousand NTD):230,108
13.Equity attributable to owners of parent end of the
period (thousand NTD):2,118,587
14.Any other matters that need to be specified:NA
